spacer
home > epc > spring 2018 > money matters
PUBLICATIONS
European Pharmaceutical Contractor

Money Matters

EPC: What are some of the challenges sites face when trying to be paid?

Dave Espenshade: A site’s ability to receive accurate and timely payments from sponsors or CROs is one of the most challenging processes it faces while conducting clinical trials. In fact, we often hear that payment terms are the biggest driver in a site’s ability to support a clinical study.

There are many reasons why this is such a challenge, with invoice adjudication being the biggest contributor to the limited transparency in the payment process. From a sponsor or CRO perspective, invoices are arriving in a variety of formats and often at different intervals. This causes a number of inconsistencies that their finance teams need to unravel to determine what work was performed, what rate was contracted, and what needs to be paid. This is a complex and difficult process, and, as a result, many sponsors and CROs pay their sites on a quarterly basis to keep up with this workload.

This time gap between services rendered and payment, along with the errors that often occur with payments, is one of the biggest challenges that sites face.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dave Espenshade is Vice President of CRO Partnerships at Greenphire. In his role, he leads the efforts to broaden the use of Greenphire’s solution suite among global CRO partners. Dave has more than two decades of experience in the software and life sciences industries and a demonstrated expertise in establishing successful partnerships between industryleading global CROs and software providers.
spacer
Dave Espenshade
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Genome & Company Chooses Luina Bio to Supply Innovative Drug Productfor Clinical Trials Programme

Luina Bio, a leading biopharmaceutical manufacturing company in Australia, today announced it will develop and produce an innovative bacterial drug product for Genome & Company to support its clinical trials programme. The relationship signals Luina Bio’s first foray into Asia and further establishes its global leadership in the current Good Manufacturing Practise for microbiome projects.
More info >>

White Papers

Pharmaceutical Companies: Outsourcing Combination Product Manufacturing

Phillips-Medisize

Combination products are therapeutics that combine two or more products (drug/device, biologics/device, biologics/drugs, or drug/device/biologics), regulated and sold as a single unit. Examples of combination products include drug-coated implantable devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
More info >>

 
Industry Events

Highly Potent Active Pharmaceutical Ingredients (HPAPI)

13-14 May 2019, Copthorne Tara Hotel, London, UK

SMi is delighted to announce its 3rd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 13th-14th May 2019. The HPAPI global market has developed rapidly in the past year and is continuing to expand into the future, with over a quarter of drugs in development worldwide being classified as highly potent. As a result, there is a growing demand for both pharmaceutical and contracted manufacturers to adapt to the evolving HPAPI landscape.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement